RegenMed: Pioneering the Future of Clinical Research

Crowdfunding Has Never Been This Easy

Invst Guru is your bi-weekly digest that explores the dynamics of equity crowdfunding. Delivered every Wednesday and Sunday, we connect startups with the power of the crowd and provide investors with access to groundbreaking ventures.

In each issue of Invst Guru, we'll spotlight the latest trends, share success stories, and offer insights from industry leaders. We aim to equip you with the knowledge and opportunities to participate effectively in equity crowdfunding, whether you're looking to fund your innovative startup or invest in potential unicorns.

🔦 Equity Crowdfunding Spotlight: RegenMed – Transforming Healthcare Through Data Innovation

In healthcare innovation, data is often called the "new oil." However, accessing, refining, and putting that data to work has historically been a costly and time-intensive process, especially in clinical research. Enter RegenMed, a SaaS healthcare company poised to revolutionize the $500 billion clinical research market with its patented Circles platform. By transforming everyday doctor-patient interactions into meaningful, real-world datasets, RegenMed is democratizing clinical research and paving the way for value-based care and AI-driven healthcare models.

As RegenMed launches its equity crowdfunding campaign on StartEngine, investors have a unique opportunity to participate in transforming an industry vital to global health and innovation.

Why RegenMed Matters

Clinical research is the backbone of medical innovation, shaping everything from breakthrough treatments to regulatory approvals. However, traditional methods of conducting clinical trials are fraught with challenges. Studies are often expensive, time-consuming, and narrowly focused on promoting high-cost products. As a result, only a tiny fraction of physicians (3%) and patients (5%) participate, leaving vast gaps in data and limiting the broader applicability of findings.

This limited participation has far-reaching consequences:

• Higher healthcare costs for providers, payers, and patients.

• Slower innovation cycles in medical research.

• Worsening healthcare outcomes, as evidenced by declining life expectancy and rising rates of preventable diseases in many regions.

RegenMed is tackling these challenges head-on. By leveraging the power of everyday healthcare interactions, the company generates evidence-based, regulatorily compliant datasets that are:

• Longitudinal (capturing trends over time).

• Unbiased (reflecting diverse patient populations).

• Cost-effective (accessible to providers of all sizes).

With Circles, RegenMed enables physicians, researchers, and product developers to collaborate seamlessly across geographies, enhancing the validity and impact of their work. This democratization of data collection and analysis isn’t just a technological advancement—it’s a paradigm shift.

The Circles Platform: How It Works

At the heart of RegenMed's innovation is the Circles platform, a comprehensive solution that streamlines collecting and analyzing clinical data. Designed with the end user in mind, Circles offers:

• Ease of Use: Physicians and researchers can effortlessly input and access data using intuitive tools available on any device.

• Global Accessibility: A cloud-based infrastructure ensures that data can be shared securely across borders, enabling collaboration among teams in different countries.

• Regulatory Compliance: Circles is HIPAA, GDPR, and GCP compliant, providing peace of mind to healthcare providers and product manufacturers.

• Scalability: Whether for a small private practice or a multinational pharmaceutical company, Circles adapts to meet the needs of its users.

This flexibility and efficiency have made Circles a standout solution in an industry hungry for innovation. RegenMed is expanding access to clinical research and driving meaningful outcomes for all stakeholders by reducing the clinical burden and cost associated with traditional trials.

The Market Opportunity: More Than Clinical Research

RegenMed’s addressable market extends well beyond clinical trials. While the $500 billion clinical research sector is a significant focus, the company is also making inroads into:

1. Value-Based Care

Healthcare is increasingly shifting from a fee-for-service model to value-based care, where providers are rewarded for improving patient outcomes. RegenMed’s datasets provide the insights necessary to design, implement, and evaluate these care models, unlocking opportunities in a market approaching $1 trillion in value.

2. Health Equity

Health disparities remain a pressing global issue. RegenMed generates unbiased, real-world evidence, empowering stakeholders to address these inequities and develop solutions tailored to underserved populations.

3. AI in Healthcare

Artificial intelligence transforms how healthcare organizations diagnose conditions, personalize treatments, and predict outcomes. RegenMed’s proprietary datasets fuel these AI models, accelerating innovation while ensuring accuracy and relevance.

Proven Traction and Financial Momentum

RegenMed isn’t just an idea—it’s a proven business with a track record of success. Over the past two years, the company has:

• Expanded its client base to over 60 provider groups and product manufacturers across North America, Europe, and Latin America.

• Generated datasets for diverse specialties, including orthopedics, neurology, compounding pharmacies, sports medicine, and sexual health.

• Achieved significant revenue growth, with recurring revenue increasing by 120% in the second half of 2023 and 309% in the first half of 2024.

Key Financial Metrics (as of July 2024):

• Average Monthly Recurring Revenue (MRR): $20,088.

• Projected Annual Recurring Revenue (ARR): $1,032,369 by year-end.

• Retention Rate: Net retained revenue of 119%, reflecting strong client satisfaction and engagement.

These figures demonstrate RegenMed’s SaaS model's scalability and the growing demand for its solutions in the healthcare industry.

Meet the Leadership Team

RegenMed’s success is driven by a team of seasoned professionals with decades of experience in healthcare, SaaS, and entrepreneurship:

• Michael P. Tierney (CEO, Co-Founder): A former private equity executive who has managed billion-dollar funds and led multiple startups to successful exits.

• Dr. J. William Futrell (Chairman, Co-Founder): A world-renowned plastic surgeon, academic, and entrepreneur with over 200 peer-reviewed publications and several patented inventions.

• Nicolas R. Tierney (COO, Co-Founder): An experienced healthcare executive who played a key role in developing RegenMed’s flagship platform and establishing its market presence.

This blend of clinical expertise and business acumen positions RegenMed for sustainable growth and long-term impact.

Why Now?

RegenMed’s equity crowdfunding campaign is pivotal in its growth trajectory. Having achieved critical milestones in product development, market penetration, and revenue generation, the company is now seeking to:

• Expand its sales force to accelerate client acquisition.

• Enhance its intellectual property portfolio to maintain a competitive edge.

• Broaden its geographic reach to serve more markets worldwide.

By participating in this campaign, investors can support RegenMed’s mission to transform healthcare while potentially benefiting from the company’s continued success.

Risks and Considerations

As with any investment, there are risks to consider. RegenMed’s campaign is speculative and involves the potential loss of your entire investment. The company’s projections are based on assumptions and may not materialize as expected. Additionally, investments in private companies are illiquid and may not provide immediate returns.

Potential investors should review all offering materials, consult their financial advisors, and understand the risks before investing.

Key Details

• Price Per Share: $9.60

• Valuation: $20 million

• Minimum Investment: $336

• Offering Type: Equity (Class B Non-Voting Common Stock)

• Funding Goal: $15,000–$1.23 million

• Deadline: December 31, 2024

Testimonials: What Clients Are Saying

RegenMed’s clients consistently highlight the value of its Circles platform in improving patient outcomes and driving medical innovation. While testimonials are anecdotal and not indicative of guaranteed results, they underscore the company’s ability to meet the needs of diverse stakeholders.

Why RegenMed Deserves Your Attention

RegenMed isn’t just disrupting an industry—it’s redefining what’s possible in healthcare. By making clinical research more accessible, efficient, and impactful, the company addresses some of the most pressing challenges in medicine today. Its innovative technology, proven market traction, and strong leadership make it a compelling choice for investors looking to make a difference while pursuing financial returns.

Don’t miss your chance to be part of this healthcare revolution.

👉 Explore the campaign on StartEngine

Today’s Sponsors 💰

This smart home company grew 200% month-over-month…

No, it’s not Ring or Nest—it’s RYSE, a leader in smart shade automation, and you can invest for just $1.75 per share.

RYSE’s innovative SmartShades have already transformed how people control their window coverings, bringing automation to homes without the need for expensive replacements. With 10 fully granted patents and a game-changing Amazon court judgment protecting their tech, RYSE is building a moat in a market projected to grow 23% annually.

This year alone, RYSE has seen revenue grow by 200% month-over-month and expanded into 127 Best Buy locations, with international markets on the horizon. Plus, with partnerships with major retailers like Home Depot and Lowe’s already in the works, they’re just getting started.

Now is your chance to invest in the company disrupting home automation—before they hit their next phase of explosive growth. But don’t wait; this opportunity won’t last long.

Invest today before their share price changes next week.

Last Issues Poll Results 🗳️:

Would You Invest In Merchagogo?

🟩🟩🟩🟩🟩🟩 👍 (13)

🟨🟨🟨🟨⬜️⬜️ 👎 (9)

🟨🟨🟨🟨🟨⬜️ 🤷 (12)

34 Votes

Follow Our Friends 👀